Immunotherapy: A Promising Alternative When Chemotherapy Fails
Immune therapy, such as the bispecific antibody treatment Columvi, is offering new hope for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when chemotherapy fails. Unlike chemotherapy drugs, antibody treatments like Columvi are more targeted and designed to spare healthy cells. Clinical trials have shown that Columvi can achieve remission in 43% of patients with DLBCL, and it has recently received approval from the FDA. Bispecific antibodies like Columvi attach to different receptor sites on cells, turning T cells into cancer-killing cells. While there is still more research to be done, bispecific antibody therapy could potentially revolutionize cancer treatment by providing more effective and tolerable options for patients.
